Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

72.13 -2.98 (-3.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,868,275
Open 75.18
Bid (Size) 69.18 (100)
Ask (Size) 76.53 (500)
Prev. Close 75.11
Today's Range 72.06 - 75.51
52wk Range 47.50 - 79.50
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?
Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The stock now trades at $75.77, marking a 35.8% gain. This was partly due to its... 
Via StockStory
Topics Stocks
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗
Via Chartmill

Performance

YTD
+2.6%
+2.6%
1 Month
+16.6%
+16.6%
3 Month
+10.8%
+10.8%
6 Month
+25.2%
+25.2%
1 Year
+34.2%
+34.2%

More News

Read More
News headline image
Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025
Via StockStory
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Halozyme Therapeutics (NASDAQ:HALO): A Prime GARP Stock with Strong Growth and Value ↗
Via Chartmill
News headline image
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Via Chartmill
News headline image
Why I Keep Buying These 10 Incredible Growth Stocks ↗
Via The Motley Fool
Topics Energy
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Affordable Growth with Strong Metrics ↗
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Technical and Fundamental Momentum ↗
Via Chartmill
News headline image
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗
Via Investor's Business Daily
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential ↗
Via Chartmill
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Halozyme (HALO) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Insights into Halozyme Therapeutics's Upcoming Earnings ↗
Via Benzinga
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method ↗
Via Chartmill
News headline image
Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million ↗
Via The Motley Fool
Topics Cannabis
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Combines Strong Growth Momentum with Technical Breakout Setup ↗
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Offers an Affordable Growth Profile ↗
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO): A Growth Stock Poised for a Breakout ↗
Via Chartmill

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 72.13
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 01/08/26 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 10.27B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.